Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.01.003Source: DataRank Database

Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy is a research paper published in Clinical Genitourinary Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.70)OA: hybridTopics (30)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Thorsten Schlomm ORCID,Stephen Bardot,Daniel Canter ORCID,Troy Scroggins,Stephen J. Freedland ORCID

Live enrichment

PubMed:33608228 OpenAlex:https://openalex.org/W3123892176

National Institutes of Health

Grant: P30CA042014

Myriad Genetics

Bayer

Huntsman Cancer Foundation

National Cancer Institute

FWCI

1.70

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.clgc.2021.01.003

publisherhttps://doi.org/10.1016/j.clgc.2021.01.003

publisherhttps://api.elsevier.com/content/article/PII:S1558767321000136?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1558767321000136?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33608228

Fields of Study

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

MeSH Terms

Androgen AntagonistsHumansMaleProstatic NeoplasmsRetrospective StudiesRisk FactorsProstate-Specific Antigen

Keywords

MedicineHazard ratioInternal medicineProstate cancerOncologyAndrogen deprivation therapyConfidence intervalProportional hazards modelAdjuvant therapyRetrospective cohort studyCohortFramingham Risk ScoreCancerRadiation therapyDiseaseMetastasisDisease ProgressionMultimodality TherapyGenomic ClassifierAdt With Radiation

Sustainable Development Goals

SDG 0: Good health and well-being